Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/SREBF1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/SREBF1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SREBF1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SREBF1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SREBF1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/SREBF1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/SREBF1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SREBF1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004343418 | Prostate | Tumor | response to peptide hormone | 113/3246 | 414/18723 | 2.24e-07 | 5.42e-06 | 113 |
GO:000698414 | Prostate | Tumor | ER-nucleus signaling pathway | 23/3246 | 46/18723 | 3.87e-07 | 8.56e-06 | 23 |
GO:003166917 | Prostate | Tumor | cellular response to nutrient levels | 66/3246 | 215/18723 | 1.00e-06 | 1.94e-05 | 66 |
GO:007137514 | Prostate | Tumor | cellular response to peptide hormone stimulus | 83/3246 | 290/18723 | 1.14e-06 | 2.16e-05 | 83 |
GO:003286915 | Prostate | Tumor | cellular response to insulin stimulus | 63/3246 | 203/18723 | 1.15e-06 | 2.18e-05 | 63 |
GO:004544414 | Prostate | Tumor | fat cell differentiation | 69/3246 | 229/18723 | 1.22e-06 | 2.28e-05 | 69 |
GO:190300814 | Prostate | Tumor | organelle disassembly | 41/3246 | 114/18723 | 1.41e-06 | 2.53e-05 | 41 |
GO:000042214 | Prostate | Tumor | autophagy of mitochondrion | 32/3246 | 81/18723 | 1.94e-06 | 3.34e-05 | 32 |
GO:006172614 | Prostate | Tumor | mitochondrion disassembly | 32/3246 | 81/18723 | 1.94e-06 | 3.34e-05 | 32 |
GO:000662617 | Prostate | Tumor | protein targeting to mitochondrion | 37/3246 | 100/18723 | 2.07e-06 | 3.56e-05 | 37 |
GO:003286815 | Prostate | Tumor | response to insulin | 75/3246 | 264/18723 | 4.94e-06 | 7.68e-05 | 75 |
GO:000926716 | Prostate | Tumor | cellular response to starvation | 50/3246 | 156/18723 | 5.17e-06 | 8.00e-05 | 50 |
GO:001050614 | Prostate | Tumor | regulation of autophagy | 86/3246 | 317/18723 | 7.77e-06 | 1.16e-04 | 86 |
GO:004259415 | Prostate | Tumor | response to starvation | 58/3246 | 197/18723 | 1.79e-05 | 2.38e-04 | 58 |
GO:003257014 | Prostate | Tumor | response to progesterone | 17/3246 | 37/18723 | 5.17e-05 | 5.67e-04 | 17 |
GO:003105612 | Prostate | Tumor | regulation of histone modification | 46/3246 | 152/18723 | 6.07e-05 | 6.59e-04 | 46 |
GO:001082116 | Prostate | Tumor | regulation of mitochondrion organization | 44/3246 | 144/18723 | 6.75e-05 | 7.21e-04 | 44 |
GO:005105112 | Prostate | Tumor | negative regulation of transport | 114/3246 | 470/18723 | 7.43e-05 | 7.82e-04 | 114 |
GO:009730518 | Prostate | Tumor | response to alcohol | 68/3246 | 253/18723 | 9.02e-05 | 8.88e-04 | 68 |
GO:190314613 | Prostate | Tumor | regulation of autophagy of mitochondrion | 15/3246 | 33/18723 | 1.65e-04 | 1.47e-03 | 15 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0493243 | Breast | DCIS | Non-alcoholic fatty liver disease | 49/846 | 155/8465 | 5.87e-14 | 1.35e-12 | 9.97e-13 | 49 |
hsa0493253 | Breast | DCIS | Non-alcoholic fatty liver disease | 49/846 | 155/8465 | 5.87e-14 | 1.35e-12 | 9.97e-13 | 49 |
hsa0493230 | Esophagus | HGIN | Non-alcoholic fatty liver disease | 66/1383 | 155/8465 | 5.21e-15 | 1.21e-13 | 9.64e-14 | 66 |
hsa04932113 | Esophagus | HGIN | Non-alcoholic fatty liver disease | 66/1383 | 155/8465 | 5.21e-15 | 1.21e-13 | 9.64e-14 | 66 |
hsa04932210 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
hsa0415210 | Esophagus | ESCC | AMPK signaling pathway | 80/4205 | 121/8465 | 1.73e-04 | 6.67e-04 | 3.42e-04 | 80 |
hsa049109 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
hsa049318 | Esophagus | ESCC | Insulin resistance | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa0493238 | Esophagus | ESCC | Non-alcoholic fatty liver disease | 122/4205 | 155/8465 | 5.69e-14 | 1.59e-12 | 8.14e-13 | 122 |
hsa0415213 | Esophagus | ESCC | AMPK signaling pathway | 80/4205 | 121/8465 | 1.73e-04 | 6.67e-04 | 3.42e-04 | 80 |
hsa0491014 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
hsa0493113 | Esophagus | ESCC | Insulin resistance | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa0493242 | Liver | HCC | Non-alcoholic fatty liver disease | 124/4020 | 155/8465 | 4.54e-17 | 2.54e-15 | 1.41e-15 | 124 |
hsa0491041 | Liver | HCC | Insulin signaling pathway | 95/4020 | 137/8465 | 1.53e-07 | 1.97e-06 | 1.10e-06 | 95 |
hsa0493121 | Liver | HCC | Insulin resistance | 77/4020 | 108/8465 | 3.89e-07 | 4.46e-06 | 2.48e-06 | 77 |
hsa049362 | Liver | HCC | Alcoholic liver disease | 89/4020 | 142/8465 | 1.73e-04 | 8.53e-04 | 4.75e-04 | 89 |
hsa0415241 | Liver | HCC | AMPK signaling pathway | 77/4020 | 121/8465 | 2.32e-04 | 1.11e-03 | 6.18e-04 | 77 |
hsa0493252 | Liver | HCC | Non-alcoholic fatty liver disease | 124/4020 | 155/8465 | 4.54e-17 | 2.54e-15 | 1.41e-15 | 124 |
hsa0491051 | Liver | HCC | Insulin signaling pathway | 95/4020 | 137/8465 | 1.53e-07 | 1.97e-06 | 1.10e-06 | 95 |
hsa0493131 | Liver | HCC | Insulin resistance | 77/4020 | 108/8465 | 3.89e-07 | 4.46e-06 | 2.48e-06 | 77 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SREBF1 | SNV | Missense_Mutation | | c.2306G>A | p.Arg769His | p.R769H | P36956 | protein_coding | deleterious(0.04) | probably_damaging(0.96) | TCGA-A8-A07G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
SREBF1 | SNV | Missense_Mutation | | c.1247N>C | p.Ser416Thr | p.S416T | P36956 | protein_coding | tolerated(0.35) | benign(0.015) | TCGA-D8-A1JD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
SREBF1 | insertion | In_Frame_Ins | novel | c.1439_1440insTGGCAG | p.Ser480_Gly481dup | p.S480_G481dup | P36956 | protein_coding | | | TCGA-E2-A1IF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
SREBF1 | SNV | Missense_Mutation | | c.3266N>A | p.Arg1089His | p.R1089H | P36956 | protein_coding | tolerated(0.55) | probably_damaging(0.999) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
SREBF1 | SNV | Missense_Mutation | | c.571N>T | p.Pro191Ser | p.P191S | P36956 | protein_coding | tolerated(0.17) | probably_damaging(0.991) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
SREBF1 | SNV | Missense_Mutation | | c.316N>G | p.Pro106Ala | p.P106A | P36956 | protein_coding | tolerated(0.29) | benign(0.143) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
SREBF1 | SNV | Missense_Mutation | novel | c.1348N>A | p.Glu450Lys | p.E450K | P36956 | protein_coding | tolerated(0.11) | probably_damaging(0.995) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
SREBF1 | SNV | Missense_Mutation | | c.1846N>T | p.Arg616Cys | p.R616C | P36956 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EK-A2RB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SREBF1 | SNV | Missense_Mutation | rs868055320 | c.3168N>T | p.Gln1056His | p.Q1056H | P36956 | protein_coding | tolerated(0.35) | benign(0.07) | TCGA-VS-A94X-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
SREBF1 | SNV | Missense_Mutation | novel | c.1040N>T | p.Ser347Phe | p.S347F | P36956 | protein_coding | tolerated(0.67) | possibly_damaging(0.7) | TCGA-VS-A94X-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6720 | SREBF1 | NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | | fluvastatin | FLUVASTATIN | |
6720 | SREBF1 | NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | | hmg coa reductase inhibitors | | 24329191 |
6720 | SREBF1 | NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | | INSULIN | INSULIN | 10627507,12576518,14594997 |
6720 | SREBF1 | NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR | | NEUROTROPHIC FACTOR | | 12788519 |